Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.86 |
| ▸ | FLT3 | P36888 | 4/20 | 0.86 |
| ▸ | BLK | P51451 | 3/20 | 0.86 |
| ▸ | JAK3 | P52333 | 1/20 | 0.69 |
| ▸ | BTK | Q06187 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18294441 | 1.00 | EGFR (0.86) | EGFRFLT3BLKJAK3BTK | |
| SCHEMBL16680603 | 0.93 | EGFR (1.00) | EGFRFLT3BLKJAK3BTK | |
| SCHEMBL30192805 | 0.93 | EGFR (1.00) | EGFRFLT3BLKJAK3BTK | |
| SCHEMBL18294436 | 0.90 | EGFR (0.87) | EGFRFLT3BLKJAK3BTK | |
| SCHEMBL30353489 | 0.90 | EGFR (0.87) | EGFRFLT3BLKJAK3BTK | |
| SCHEMBL20080239 | 0.90 | EGFR (0.69) | EGFRFLT3BLKJAK3 | |
| SCHEMBL18294430 | 0.87 | EGFR (0.87) | EGFRFLT3BLKJAK3BTK | |
| SCHEMBL30353469 | 0.87 | EGFR (0.87) | EGFRFLT3BLKJAK3BTK | |
| SCHEMBL18294437 | 0.87 | EGFR (0.82) | EGFRFLT3BLKJAK3BTK | |
| SCHEMBL18294440 | 0.87 | EGFR (0.86) | EGFRFLT3BLKJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922417-B | Use of pteridinone derivatives as EGFR inhibitors | 上海壹典医药科技开发有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-11306095-B2 | Use of pteridinone derivative serving as EGFR inhibitor | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306095-B2 | Use of pteridinone derivative serving as EGFR inhibitor | EGFR, ERBB2, ERBB3 | EGFR 1/4885FLT3 20/4885BLK 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.